Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial.-MedSci.cn

Intraperitoneal immunotherapy with the bispecific anti-EpCAM x anti-CD3 directed antibody catumaxomab for patients with peritoneal carcinomatosis from gastric cancer: Final results of a randomized phase II AIO trial.

Lordick, F; Kunzmann, V; Trojan, J; Daum, S; Schenk, M; Kullmann, F; Schroll, S; Behringer, DM; Stahl, M; Al-Batran, SE; Ibach, S; Koerfer, J; Knoedler, MK

JOURNAL OF CLINICAL ONCOLOGY, 2018; 36 (4):

科室
- - 订阅+
  - 更多科室
工具
服务